Does the media favor RNXT or LSTA?

In the previous week, Lisata Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Lisata Therapeutics and 3 mentions for RenovoRx. Lisata Therapeutics' average media sentiment score of 0.72 beat RenovoRx's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LSTA or EXOZ?

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 1,215.79%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LSTA or EXOZ more profitable?

Lisata Therapeutics' return on equity of -103.54% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% eXoZymes N/A -220.63% -141.26%

Does the media prefer LSTA or EXOZ?

In the previous week, Lisata Therapeutics had 3 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Lisata Therapeutics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Lisata Therapeutics' score of 0.72 indicating that eXoZymes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LSTA or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lisata Therapeutics $170K 61.09 -$16.59M -$1.86 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is LSTA or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Alterity Therapeutics N/A N/A N/A

Does the media prefer LSTA or ATHE?

In the previous week, Lisata Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for Alterity Therapeutics. Lisata Therapeutics' average media sentiment score of 0.72 beat Alterity Therapeutics' score of -0.39 indicating that Lisata Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lisata Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BHST or LSTA?

In the previous week, Lisata Therapeutics had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for BioHarvest Sciences. Lisata Therapeutics' average media sentiment score of 0.72 beat BioHarvest Sciences' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioHarvest Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lisata Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LSTA or APLM?

Lisata Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 1,215.79%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, LSTA or APLM?

Apollomics has higher revenue and earnings than Lisata Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lisata Therapeutics $170K 61.09 -$16.59M -$1.86 N/A Apollomics $8.50M 4.47 -$10.94M N/A N/A

Is LSTA or APLM more profitable?

Apollomics' return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% Apollomics N/A N/A N/A

Lisata Therapeutics (LSTA) Competitors

$1.14 +0.10 (+9.62%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$1.18 +0.04 (+3.60%)

As of 04:00 AM Eastern

Compare

LSTA vs. RNXT, EXOZ, ATHE, BHST, and APLM

Should you buy Lisata Therapeutics stock or one of its competitors? MarketBeat compares Lisata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lisata Therapeutics include RenovoRx (RNXT), eXoZymes (EXOZ), Alterity Therapeutics (ATHE), BioHarvest Sciences (BHST), and Apollomics (APLM).

How does Lisata Therapeutics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RenovoRx has higher revenue and earnings than Lisata Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	41.83	-$11.17M	-$0.33	N/A
Lisata Therapeutics	$170K	61.09	-$16.59M	-$1.86	N/A

In the previous week, Lisata Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Lisata Therapeutics and 3 mentions for RenovoRx. Lisata Therapeutics' average media sentiment score of 0.72 beat RenovoRx's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

RenovoRx presently has a consensus price target of $8.50, suggesting a potential upside of 717.31%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 1,215.79%. Given Lisata Therapeutics' higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Lisata Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Lisata Therapeutics' return on equity of -103.54% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Lisata Therapeutics	N/A	-103.54%	-83.08%

Summary

Lisata Therapeutics beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does Lisata Therapeutics compare to eXoZymes?

Lisata Therapeutics (NASDAQ:LSTA) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

8.9% of Lisata Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

eXoZymes has lower revenue, but higher earnings than Lisata Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	61.09	-$16.59M	-$1.86	N/A
eXoZymes	$70K	607.86	-$9.16M	-$1.14	N/A

Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 1,215.79%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lisata Therapeutics had 3 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Lisata Therapeutics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.85 beat Lisata Therapeutics' score of 0.72 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, meaning that its share price is 193% more volatile than the broader market.

Lisata Therapeutics' return on equity of -103.54% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
eXoZymes	N/A	-220.63%	-141.26%

Summary

Lisata Therapeutics beats eXoZymes on 8 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Alterity Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Lisata Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 1,215.79%. Alterity Therapeutics has a consensus target price of $13.00, indicating a potential upside of 196.13%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Alterity Therapeutics	N/A	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than Lisata Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	61.09	-$16.59M	-$1.86	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lisata Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

In the previous week, Lisata Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for Alterity Therapeutics. Lisata Therapeutics' average media sentiment score of 0.72 beat Alterity Therapeutics' score of -0.39 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lisata Therapeutics and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Lisata Therapeutics compare to BioHarvest Sciences?

BioHarvest Sciences (NASDAQ:BHST) and Lisata Therapeutics (NASDAQ:LSTA) are related small-cap companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Lisata Therapeutics has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -32.54%. BioHarvest Sciences' return on equity of -76.03% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-32.54%	-76.03%	-25.30%
Lisata Therapeutics	N/A	-103.54%	-83.08%

BioHarvest Sciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

8.9% of Lisata Therapeutics shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lisata Therapeutics had 2 more articles in the media than BioHarvest Sciences. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for BioHarvest Sciences. Lisata Therapeutics' average media sentiment score of 0.72 beat BioHarvest Sciences' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioHarvest Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

BioHarvest Sciences presently has a consensus target price of $10.00, indicating a potential upside of 342.48%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 1,215.79%. Given Lisata Therapeutics' higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than BioHarvest Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioHarvest Sciences has higher revenue and earnings than Lisata Therapeutics. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioHarvest Sciences	$34.51M	1.28	-$11.14M	-$0.59	N/A
Lisata Therapeutics	$170K	61.09	-$16.59M	-$1.86	N/A

Summary

BioHarvest Sciences and Lisata Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Lisata Therapeutics compare to Apollomics?

Lisata Therapeutics (NASDAQ:LSTA) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lisata Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Apollomics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Apollomics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
Apollomics	N/A	N/A	N/A

Apollomics has higher revenue and earnings than Lisata Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	61.09	-$16.59M	-$1.86	N/A
Apollomics	$8.50M	4.47	-$10.94M	N/A	N/A

Lisata Therapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 1,215.79%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lisata Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lisata Therapeutics had 4 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Lisata Therapeutics and 0 mentions for Apollomics. Lisata Therapeutics' average media sentiment score of 0.72 beat Apollomics' score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lisata Therapeutics	Positive
Apollomics	Neutral

Summary

Lisata Therapeutics and Apollomics tied by winning 6 of the 12 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.47M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-0.61	7.32	279.15	25.53
Price / Sales	61.09	1,269.15	587.36	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	0.69	17.36	13.06	6.11
Net Income	-$16.59M	-$12.52M	$3.48B	$347.58M
7 Day Performance	4.59%	3.64%	3.38%	4.91%
1 Month Performance	-65.77%	-5.38%	-2.81%	-2.06%
1 Year Performance	-60.96%	49.44%	73.07%	21.03%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	2.5753 of 5 stars	$1.14 +9.6%	$15.00 +1,215.8%	-55.6%	$9.47M	$170K	N/A	30	News Coverage Upcoming Earnings
RNXT RenovoRx	3.6481 of 5 stars	$0.90 -1.0%	$8.50 +846.4%	-14.0%	$40.88M	$1.12M	N/A	6	News Coverage Positive News
EXOZ eXoZymes	0.4881 of 5 stars	$4.49 +2.0%	N/A	-53.5%	$40.53M	$70K	N/A	29	News Coverage Gap Up
ATHE Alterity Therapeutics	2.9131 of 5 stars	$4.60 +0.5%	$13.00 +182.9%	-15.7%	$40.48M	N/A	N/A	10	Gap Up
BHST BioHarvest Sciences	2.1463 of 5 stars	$2.19 +7.4%	$10.00 +356.6%	-70.5%	$40.02M	$34.51M	N/A	N/A	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. RNXT, EXOZ, ATHE, BHST, and APLM

How does Lisata Therapeutics compare to RenovoRx?

Summary

How does Lisata Therapeutics compare to eXoZymes?

Summary

How does Lisata Therapeutics compare to Alterity Therapeutics?

Summary

How does Lisata Therapeutics compare to BioHarvest Sciences?

Summary

How does Lisata Therapeutics compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. RNXT, EXOZ, ATHE, BHST, and APLM

How does Lisata Therapeutics compare to RenovoRx?

Which has more volatility & risk, RNXT or LSTA?

Do institutionals and insiders hold more shares of RNXT or LSTA?

Which has preferable valuation & earnings, RNXT or LSTA?

Does the media favor RNXT or LSTA?

Do analysts prefer RNXT or LSTA?

Is RNXT or LSTA more profitable?

Summary

How does Lisata Therapeutics compare to eXoZymes?

Do insiders & institutionals believe in LSTA or EXOZ?

Which has higher valuation and earnings, LSTA or EXOZ?

Do analysts prefer LSTA or EXOZ?

Does the media prefer LSTA or EXOZ?

Which has more volatility & risk, LSTA or EXOZ?

Is LSTA or EXOZ more profitable?

Summary

How does Lisata Therapeutics compare to Alterity Therapeutics?

Do analysts recommend LSTA or ATHE?

Is LSTA or ATHE more profitable?

Which has stronger earnings & valuation, LSTA or ATHE?

Do institutionals and insiders believe in LSTA or ATHE?

Which has more volatility and risk, LSTA or ATHE?

Does the media prefer LSTA or ATHE?

Summary

How does Lisata Therapeutics compare to BioHarvest Sciences?

Is BHST or LSTA more profitable?

Which has more risk & volatility, BHST or LSTA?

Do insiders & institutionals believe in BHST or LSTA?

Does the media favor BHST or LSTA?

Do analysts prefer BHST or LSTA?

Which has preferable earnings & valuation, BHST or LSTA?

Summary

How does Lisata Therapeutics compare to Apollomics?

Do institutionals & insiders hold more shares of LSTA or APLM?

Which has more risk and volatility, LSTA or APLM?

Is LSTA or APLM more profitable?

Which has stronger earnings & valuation, LSTA or APLM?

Do analysts rate LSTA or APLM?

Does the media refer more to LSTA or APLM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools